Predictive factors of early and late transfusions after CAR T-cell therapy
| A . | Transfusion in the early phase (<1 month) . | |||
|---|---|---|---|---|
| RBC . | Platelets . | |||
| aOR (95% CI) . | P value . | aOR (95% CI) . | P value . | |
| Age >60 y at infusion | 2.06 (1.38-3.07) | .0004 | 1.61 (1.09-2.38) | .0175 |
| ≥1 transfusion (RBC or platelets) within 6 mo before CAR T-cell therapy | 9.71 (6.37-14.71) | <.0001 | 7.35 (4.74-11.49) | <.0001 |
| High (≥2) CAR-HEMATOTOX score | 2.01 (1.34-3.01) | .0007 | 2.42 (1.60-3.66) | <.0001 |
| Treatment with axi-cel (vs tisa-cel) | 2.02 (1.34-3.05) | .0008 | 2.12 (1.40-3.19) | .0004 |
| ECOG PS ≥2 at infusion | 2.86 (1.62-5.04) | .0004 | 2.28 (1.35-3.87) | .0028 |
| A . | Transfusion in the early phase (<1 month) . | |||
|---|---|---|---|---|
| RBC . | Platelets . | |||
| aOR (95% CI) . | P value . | aOR (95% CI) . | P value . | |
| Age >60 y at infusion | 2.06 (1.38-3.07) | .0004 | 1.61 (1.09-2.38) | .0175 |
| ≥1 transfusion (RBC or platelets) within 6 mo before CAR T-cell therapy | 9.71 (6.37-14.71) | <.0001 | 7.35 (4.74-11.49) | <.0001 |
| High (≥2) CAR-HEMATOTOX score | 2.01 (1.34-3.01) | .0007 | 2.42 (1.60-3.66) | <.0001 |
| Treatment with axi-cel (vs tisa-cel) | 2.02 (1.34-3.05) | .0008 | 2.12 (1.40-3.19) | .0004 |
| ECOG PS ≥2 at infusion | 2.86 (1.62-5.04) | .0004 | 2.28 (1.35-3.87) | .0028 |
| B . | Transfusion in the late phase (≥1 mo) . | |||
|---|---|---|---|---|
| RBC . | Platelets . | |||
| aOR (95% CI) . | P value . | aOR (95% CI) . | P value . | |
| ≥1 transfusion (RBC or platelets) within 6 mo before CAR T-cell therapy | 5.43 (3.37-8.85) | <.0001 | 7.75 (4.65-12.99) | <.0001 |
| High (≥2) CAR-HEMATOTOX score | 1.98 (1.27-3.09) | .0026 | 2.15 (1.37-3.37) | .0008 |
| ICANS grade ≥3 | 3.01 (1.62-5.59) | .0005 | NS | |
| Tocilizumab use | NS | 1.85 (1.15-2.98) | .0118 | |
| B . | Transfusion in the late phase (≥1 mo) . | |||
|---|---|---|---|---|
| RBC . | Platelets . | |||
| aOR (95% CI) . | P value . | aOR (95% CI) . | P value . | |
| ≥1 transfusion (RBC or platelets) within 6 mo before CAR T-cell therapy | 5.43 (3.37-8.85) | <.0001 | 7.75 (4.65-12.99) | <.0001 |
| High (≥2) CAR-HEMATOTOX score | 1.98 (1.27-3.09) | .0026 | 2.15 (1.37-3.37) | .0008 |
| ICANS grade ≥3 | 3.01 (1.62-5.59) | .0005 | NS | |
| Tocilizumab use | NS | 1.85 (1.15-2.98) | .0118 | |
The table presents a multivariate analysis.
Factors tested in the multivariate analysis but not predictive were age-adjusted international prognostic index (aaIPI) a diagnostic, refractoriness to firstline treatment, prior autologous stem cell transplantation, chemotherapy within 6 months before CAR T-cell therapy, chemotherapy as bridging therapy, bulky disease (>5 cm) at infusion, CRS grade ≥3, corticosteroids use after CAR T-cell infusion, intensive care unit (ICU) admission after CAR T-cell infusion, erythropoietin (EPO) use after CAR T-cell infusion, and granulocyte-colony stimulating factor (G-CSF) use after CAR T-cell infusion.
NS, non-significant.